Healthcare Industry News: Wharton's Jelly
News Release - July 20, 2006
Stem Cell Authority Ltd.(TM) Offers Ethical Alternative to Alleviate Political Stem Cell Deadlock Between U.S. Congress and PresidentAKRON, Ohio, July 20 (HSMN NewsFeed) -- The U.S. Senate passed the controversial Bill # H.R. 810 to amend the Public Health Service Act to provide federal funding for human embryonic stem cell research. President Bush exercised his first ever presidential veto yesterday in the Rose Garden to block that legislation. Stem Cell Authority Ltd. offers an ethical and non- controversial alternative to the national embryonic stem cell debate.
The use of embryonic stem cells is hotly debated because many scientists believe that embryonic stem cells have the potential to develop into all of the tissues of the body. The ethical alternative offered by Stem Cell Authority Ltd. is the use of Wharton's Jelly matrix stem cells. Recent evidence indicates that the Wharton's Jelly matrix stem cells can differentiate into neurons, glia, skeletal muscle cells, heart muscle cells, bone cells, cartilage cells and liver cells. Published work indicates that the human umbilical cord Wharton's Jelly matrix stem cells are therapeutically useful in an animal model of Parkinson's disease. Therefore, the Wharton's Jelly matrix stem cells may have the potential for treating neurological diseases. In contrast, umbilical cord blood stem cells are used clinically to treat conditions calling for bone marrow stem cell transplant. These diseases include certain cancers and in-borne errors in metabolism.
Stem Cell Authority Ltd.'s subsidiary company, OB/GYN CellSECURE, Inc., presents an ethical alternative to embryonic stem cells, as the company is the exclusive licensee of technology developed by KSU, which allows for the collection of the matrix stem cells from the Wharton's Jelly which is within the human umbilical cord. The collection is accomplished safely and painlessly without risk to the child after birth, and the collection of the matrix stem cell is compatible with collection of umbilical cord blood stem cells. Thus, Stem Cell Authority Ltd. presents a non-controversial alternative to obtain human stem cells for cryogenic storage of umbilical cord blood and the matrix stem cells. Stem Cell Authority Ltd., through its subsidiary, has the exclusive right to offer this service to its customers, placing it in a strong position within the biotech market.
The Kansas State University Research Foundation (KSURF) has filed an application for a patent pertaining to the methods for the collection, storage, biotechnology and therapeutic use of umbilical cord matrix stem cells. Stem Cell Authority Ltd., through its subsidiary OB/GYN CellSECURE, Inc., has the exclusive license granted by KSURF to collect and cryogenically store human pluripotent umbilical cord matrix stem cells, making it the only United States entity that is permitted to perform the collection and storage of these stem cells, which have the potential to be one of the most important sources of stem cells available. The company believes it is poised to become a market leader in this expanding biotech industry.
NASDAQ authorized Stem Cell Authority Ltd. (OTC: SCAL ), to be publicly traded on July 7, 2006.
Cautionary Statement: This news release may contain certain forward- looking statements within the meaning of Section 27A of the Securities and Exchange Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainties. Although Stem Cell Authority Ltd. believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any assumption could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included herein, the inclusion should not be regarded as a representation by Stem Cell Authority Ltd. or any other person that the objection and plans of Stem Cell Authority Ltd. will be achieved.
Source: Stem Cell Authority
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.